Johnson & Johnson Vision to Acquire TearScience
Johnson & Johnson Vision announced through a company press release Friday that it will acquire TearScience through Abbott Medical Optics, which J & J previously acquired in fall 2016. The terms of the deal are expected to be released before the end of the year.
TearScience are the developers of “an office-based approach to imaging and treating meibomian gland dysfunction.”
“Dry Eye is a significant unmet health need globally, and Meibomian Gland Dysfunction is the cause for more than 60% of people living with this condition,” said Ashley McEvoy, Company Group Chairman of Johnson & Johnson Vision. “The innovative portfolio from TearScience positively impacts the lives of patients around the world suffering from this chronic condition. These solutions, coupled with our existing contact lens and surgical portfolio, will allow us to help more patients with their vision needs, throughout their lifetime.”